JELD-WEN (NYSE:JELD) Beats Q1 Sales Targets But Stock Drops
Building products manufacturer JELD-WEN (NYSE:JELD) reported Q1 CY2025 results exceeding the market's revenue expectations , but sales fell by 19.1% year on year to $776 million. Its non-GAAP loss of $0.17 per share was 10.2% above analysts' consensus estimates.
Is now the time to buy JELD-WEN? Find out in our full research report.
Revenue: $776 million vs analyst estimates of $769.6 million (19.1% year-on-year decline, 0.8% beat)
Adjusted EPS: -$0.17 vs analyst estimates of -$0.19 (10.2% beat)
Adjusted EBITDA: $21.9 million vs analyst estimates of $20.76 million (2.8% margin, 5.5% beat)
Operating Margin: -22.1%, down from -3% in the same quarter last year
Free Cash Flow was -$120.3 million compared to -$45.7 million in the same quarter last year
Organic Revenue fell 15% year on year (-13.5% in the same quarter last year)
Market Capitalization: $492.6 million
"While market conditions remained very challenging during the first quarter, they developed mostly as expected," said Chief Executive Officer William J. Christensen.
Founded in the 1960s as a general wood-making company, JELD-WEN (NYSE:JELD) manufactures doors, windows, and other related building products.
Reviewing a company's long-term sales performance reveals insights into its quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. JELD-WEN's demand was weak over the last five years as its sales fell at a 3.3% annual rate. This was below our standards and suggests it's a low quality business.
Long-term growth is the most important, but within industrials, a half-decade historical view may miss new industry trends or demand cycles. JELD-WEN's recent performance shows its demand remained suppressed as its revenue has declined by 11.4% annually over the last two years.
We can better understand the company's sales dynamics by analyzing its organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don't accurately reflect its fundamentals. Over the last two years, JELD-WEN's organic revenue averaged 12% year-on-year declines. Because this number aligns with its normal revenue growth, we can see the company's core operations (not acquisitions and divestitures) drove most of its results.
This quarter, JELD-WEN's revenue fell by 19.1% year on year to $776 million but beat Wall Street's estimates by 0.8%.
Looking ahead, sell-side analysts expect revenue to decline by 7.3% over the next 12 months. Although this projection is better than its two-year trend, it's hard to get excited about a company that is struggling with demand.
Software is eating the world and there is virtually no industry left that has been untouched by it. That drives increasing demand for tools helping software developers do their jobs, whether it be monitoring critical cloud infrastructure, integrating audio and video functionality, or ensuring smooth content streaming. Click here to access a free report on our 3 favorite stocks to play this generational megatrend.
Operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses – everything from the cost of goods sold to advertising and wages. It's also useful for comparing profitability across companies with different levels of debt and tax rates because it excludes interest and taxes.
JELD-WEN was profitable over the last five years but held back by its large cost base. Its average operating margin of 1.6% was weak for an industrials business. This result isn't too surprising given its low gross margin as a starting point.
Analyzing the trend in its profitability, JELD-WEN's operating margin decreased by 12.5 percentage points over the last five years. JELD-WEN's performance was poor no matter how you look at it - it shows that costs were rising and it couldn't pass them onto its customers.
In Q1, JELD-WEN generated an operating profit margin of negative 22.1%, down 19.2 percentage points year on year. Since JELD-WEN's operating margin decreased more than its gross margin, we can assume it was less efficient because expenses such as marketing, R&D, and administrative overhead increased.
We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable.
Sadly for JELD-WEN, its EPS declined by 18% annually over the last five years, more than its revenue. This tells us the company struggled because its fixed cost base made it difficult to adjust to shrinking demand.
Diving into the nuances of JELD-WEN's earnings can give us a better understanding of its performance. As we mentioned earlier, JELD-WEN's operating margin declined by 12.5 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; taxes and interest expenses can also affect EPS but don't tell us as much about a company's fundamentals.
Like with revenue, we analyze EPS over a more recent period because it can provide insight into an emerging theme or development for the business.
For JELD-WEN, its two-year annual EPS declines of 49.7% show it's continued to underperform. These results were bad no matter how you slice the data.
In Q1, JELD-WEN reported EPS at negative $0.17, down from $0.21 in the same quarter last year. Despite falling year on year, this print easily cleared analysts' estimates. Over the next 12 months, Wall Street expects JELD-WEN's full-year EPS of $0.40 to grow 51.9%.
We were impressed by how significantly JELD-WEN blew past analysts' organic revenue expectations this quarter. We were also glad its EPS and EBITDA outperformed Wall Street's estimates. Zooming out, we think this quarter featured some important positives, but shares traded down 6.3% to $5.25 immediately after reporting.
Is JELD-WEN an attractive investment opportunity right now? When making that decision, it's important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here, it's free.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Associated Press
18 minutes ago
- Associated Press
Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results
NEWARK, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT), today reported its financial results for the third quarter and first nine months of fiscal year 2025 ended April 30, 2025. 'We are pleased to have completed our merger with Cyclo Therapeutics and look forward to reporting the topline data from the 48-week interim analysis of the pivotal Phase 3 TransportNPC ™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 anticipated later this month,' said Howard Jonas, Chief Executive Officer, Executive Chairman and Chairman of the Board of Rafael Holdings. Mr. Jonas added, 'We have enhanced our financial position with the closing of a $25 million rights offering earlier this month which will support advancing this potential new treatment option for patients suffering from this rare genetic disease.' Rafael Holdings, Inc. Third Quarter Fiscal Year 2025 Financial Results As of April 30, 2025, we had cash and cash equivalents of $37.9 million. On June 4, 2025, the Company announced the closing of a $25 million rights offering, which, including the funding of the backstop commitment by the Jonas family, raised net proceeds of $24.9 million after deduction of certain expenses incurred in connection with the offering. For the three months ended April 30, 2025, we recorded a net loss attributable to Rafael Holdings of $4.8 million, or $0.19 per share, versus a net loss of $32.4 million, or $1.36 per share in the year ago period. The year over year decrease in net loss is attributable to non-cash items, primarily unrealized losses of $1.4 million on the Company's investment in Cyclo equity which we purchased in advance of the potential merger in the current period versus $4.4 million in the year ago period, combined with an in-process R&D expense of $89.9 million related to the acquisition of Cornerstone, partially offset by a $31.3 million recovery of receivables from Cornerstone in the year ago period. Research and development expenses were $3.0 million for the three months ended April 30, 2025, compared to $1.5 million in the year ago period. The year over year increase relates to the inclusion in the current year period of spending at Cyclo Therapeutics following the March 25, 2025 merger and the activity of Cornerstone and Day Three which were consolidated with Rafael Holdings during fiscal 2024. General and administrative expenses were $3.2 million for the three months ended April 30, 2025, compared to $1.9 million in the year ago period. The year over year increase relates to the inclusion of Cyclo Therapeutics following closing of the merger, and the activity of Cornerstone and Day Three, following their consolidation. Rafael Holdings, Inc. First Nine Months Fiscal Year 2025 Financial Results For the nine months ended April 30, 2025, we recorded a net loss attributable to Rafael Holdings of $18.4 million, or $0.73 per share, versus a net loss of $29.9 million, or $1.26 per share in the year ago period. The year over year decrease in net loss is attributable to in-process R&D expense of $89.9 million related to the acquisition of Cornerstone net with a $31.3 million recovery of receivables from Cornerstone in the year ago period and $3.2 million in unrealized gains on the Company's investment in Cyclo equity. Research and development expenses were $5.3 million for the nine months ended April 30, 2025, compared to $2.6 million in the year ago period. The year over year increase relates to the merger with Cyclo Therapeutics which closed on March 25, 2025, and the activity of Cornerstone and Day Three, which were consolidated with Rafael Holdings during fiscal 2024. For the nine months ended April 30, 2025, general and administrative expenses were $8.3 million compared to $6.5 million in the same period in the prior year. The year over year increase relates to the merger with Cyclo Therapeutics which closed on March 25, 2025, and the activity of Cornerstone and Day Three, which were consolidated with Rafael Holdings during fiscal 2024. About Rafael Holdings, Inc. Rafael Holdings, Inc. holds interests in clinical and early-stage pharmaceutical and certain other companies, including our wholly owned subsidiary, Cyclo Therapeutics, LLC, a clinical stage biotechnology company dedicated to developing Rafael's lead clinical candidate, Trappsol® Cyclo™, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 ('NPC1'), a rare, fatal, and progressive genetic disorder. Rafael also holds majority equity interests in LipoMedix Pharmaceuticals Ltd., a clinical stage pharmaceutical company, Cornerstone Pharmaceuticals, Inc., formerly known as Rafael Pharmaceuticals Inc., a cancer metabolism-based therapeutics company, Rafael Medical Devices, LLC, an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries, and Day Three Labs, Inc., a company which empowers third-party manufacturers to reimagine their existing cannabis offerings. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; plans regarding the further evaluation of clinical data; and the potential of our pipeline, including our internal cancer metabolism research programs. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, those disclosed under the caption 'Risk Factors' in our Annual Report on Form 10-K for the year ended July 31, 2024, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. Contact: Barbara Ryan [email protected] (203) 274-2825


Associated Press
18 minutes ago
- Associated Press
EBC Financial Group Launches over a 100 U.S. ETF CFDs, Strengthening Diversification for Global Clients
LONDON, June 11, 2025 (GLOBE NEWSWIRE) -- EBC Financial Group (EBC) has announced the launch of over 100 new U.S.-listed Exchange-Traded Fund (ETF) CFDs, expanding its multi-asset product suite and offering global client's deeper access to diversified, thematic trading opportunities. The rollout highlights EBC's ongoing commitment to delivering institutional-grade tools across asset classes, underpinned by flexibility, transparency, and efficiency. The new offering includes ETFs listed on the NYSE and NASDAQ, issued by leading asset managers such as Vanguard, iShares (BlackRock), and State Street Global Advisors. Thematic coverage spans a wide range of global macro and sectoral narratives. 'This expansion reflects our vision to bridge intelligent product design with market relevance,' said David Barrett, CEO of EBC Financial Group (UK) Ltd. 'The new products are a natural evolution for traders seeking targeted exposure with greater strategic flexibility. At EBC, we're building an ecosystem that empowers both precision and performance.' Thematic Access Meets Tactical Flexibility The additional ETF-linked instruments cover a variety of market exposures, including geographic allocations like the iShares MSCI Brazil ETF; fixed income-focused strategies such as the iShares iBoxx $ High Yield Corporate Bond Fund; and sector- or commodity-based indices including the United States Oil Fund LP and the Vanguard Health Care ETF. Other themes include dividend-related baskets, mid-cap equities, and style-based index tracking. These developments reflect wider industry interest in instruments that mirror trends in asset allocation without direct ownership of the underlying securities. Across many markets, sector-tilted and style-based index products are gaining relevance as participants seek flexible ways to align with global narratives. Historically, ETFs tracking specific economic cycles—such as commodity recoveries or emerging market rebounds—have demonstrated performance differentiation. The iShares MSCI Brazil ETF, for example, notably outperformed the S&P 500 during the post-pandemic recovery period in 2021, highlighting how thematic instruments can diverge from broad indices depending on market cycles. These additions serve as both stand-alone trade ideas and complementary instruments alongside EBC's existing product lineup, enabling advanced portfolio structuring and thematic trading. Smarter Exposure: Leverage, Shorting, and Cost Efficiency in One Product Compared to direct ETF investments, it presents several key advantages as traders benefit from a simplified cost structure, with no traditional fund management fees or broker commissions. The flexibility to take both long and short positions allows for strategic trading regardless of market direction, while the use of leverage enhances capital efficiency and return potential. These trades are executed in real time via EBC's recognised platforms, providing seamless access to market opportunities. During key market cycles, for example the post-pandemic V-shaped recovery of 2021—certain thematic ETFs, like the iShares MSCI Brazil ETF, significantly outperformed broader indices such as the S&P 500. Our portfolio enables traders to participate in similar trends, adapting quickly to shifting market dynamics with precision and speed. Getting Started These products can be accessed by registering on to begin simulated or live trading. About EBC Financial Group Founded in London's esteemed financial district, EBC Financial Group (EBC) is a global brand known for its expertise in financial brokerage and asset management. Through its regulated entities operating across major financial jurisdictions—including the UK, Australia, the Cayman Islands, Mauritius, and others—EBC enables retail, professional, and institutional investors to access a wide range of global markets and trading opportunities, including currencies, commodities, shares, and indices. Recognised with multiple awards, EBC is committed to upholding ethical standards and is licensed and regulated within the respective jurisdictions. EBC Financial Group (UK) Limited is regulated by the UK's Financial Conduct Authority (FCA); EBC Financial Group (Cayman) Limited is regulated by the Cayman Islands Monetary Authority (CIMA); EBC Financial Group (Australia) Pty Ltd, and EBC Asset Management Pty Ltd are regulated by Australia's Securities and Investments Commission (ASIC); EBC Financial (MU) Ltd is authorised and regulated by the Financial Services Commission Mauritius (FSC). At the core of EBC are a team of industry veterans with over 40 years of experience in major financial institutions. Having navigated key economic cycles from the Plaza Accord and 2015 Swiss franc crisis to the market upheavals of the COVID-19 pandemic. We foster a culture where integrity, respect, and client asset security are paramount, ensuring that every investor relationship is handled with the utmost seriousness it deserves. As the Official Foreign Exchange Partner of FC Barcelona, EBC provides specialised services across Asia, LATAM, the Middle East, Africa, and Oceania. Through its partnership with United to Beat Malaria, the company contributes to global health initiatives. EBC also supports the 'What Economists Really Do' public engagement series by Oxford University's Department of Economics, helping to demystify economics and its application to major societal challenges, fostering greater public understanding and dialogue. Media Contact: Savitha Ravindran Global Public Relations Manager s[email protected] Michelle Siow Brand & Communications Director [email protected]

Associated Press
18 minutes ago
- Associated Press
Herbalife's Aloin Identification Method for Aloe Vera Officially Recognized by AOAC INTERNATIONAL
LOS ANGELES--(BUSINESS WIRE)--Jun 11, 2025-- Herbalife Ltd. (NYSE: HLF), a premier health and wellness company, community and platform, today announced the Association of Official Analytical Collaboration (AOAC INTERNATIONAL) —a global authority in analytical science—has formally certified its proprietary method for identifying and measuring anthraquinones, also known as aloins, in aloe vera. Aloe regulatory groups require producers of ingestible aloe vera products to monitor naturally occurring compounds such as aloin A, aloin B, and aloe-emodin to meet safety guidelines. This certification officially recognizes Herbalife's longstanding method as the world's first AOAC-approved approach for detecting aloins—reinforcing safety and quality benchmarks across botanical and dietary supplement industries. This press release features multimedia. View the full release here: Herbalife's method for identifying aloin in aloe vera receives official recognition from AOAC INTERNATIONAL. Developed by Herbalife scientists and validated by independent laboratories worldwide, this AOAC-certified method is used to test every batch of Herbalife's aloe-based products, ensuring safety, while preserving aloe vera's natural benefits. Aloe vera is a key ingredient in many of Herbalife's top products, which are sold in more than 90 markets. 'This AOAC validation is an important milestone for Herbalife and the industry as a whole,' said Gary Swanson, SVP of Global Quality at Herbalife and lead author of the study. 'We are proud to lead scientific innovation that enhances botanical ingredient safety, benefitting not only Herbalife products and our customers, but also advancing standards across the industry.' Herbalife's method was validated through a global multi-laboratory study involving eight independent laboratories. Each lab tested the same set of six aloe vera samples, including both raw materials and finished products, using HPLC (High-Performance Liquid Chromatography) to measure aloin A, aloin B, and aloe-emodin. The study ensured the method's accuracy and reliability across various labs and product types, with results confirming that it met all performance criteria, including precision and system suitability. 'This multi-laboratory validation study supported approval of an analytical method developed by Herbalife scientists as the AOAC 2016.09 Official Final Action Method,' said Dr. Katerina Mastovska, deputy executive director and chief science officer, AOAC INTERNATIONAL. 'AOAC official methods undergo rigorous scientific evaluation and are highly credible and globally accepted. As such, this method will help strengthen botanical quality and safety standards worldwide.' Herbalife has a long-standing commitment to aloe vera research and quality assurance. This dedication has resulted in five patents and three published studies focused on developing safe extraction methods that preserve the plant's natural benefits. While many companies rely solely on supplier certifications to confirm the authenticity of their aloe vera, Herbalife goes further. The company is one of the few in the world using advanced proton nuclear magnetic resonance (NMR) spectrometry—an analytical technique that uses magnetic fields and radio waves to identify the molecular structure of raw materials. This allows Herbalife to independently verify the identity and purity of its aloe vera at the molecular level, ensuring the highest standards of quality, consistency and traceability across its global supply chain. For 45 years, Herbalife has upheld a global commitment to quality through its rigorous Seed to Feed process. This comprehensive system ensures that every ingredient—from responsibly sourced crops cultivated by dedicated farmers to the finished product—meets stringent standards for identity, potency, safety, and purity. Herbalife performs internal testing in ISO 17025-accredited laboratories, verifying that ingredients comply with both company standards and government regulations. The company's science-backed approach, grounded in Good Manufacturing Practices (GMPs) and NSF International standards, delivers consistent, transparent products in more than 90 markets. Supported by a global team of scientists and quality experts, this process strengthens consumer trust and continues to advance industry standards worldwide. Herbalife's aloe vera testing method has been published in Journal of AOAC INTERNATIONAL (Volume 108, Issue 3, Pages 449-471). About Herbalife Ltd. Herbalife (NYSE: HLF) is a premier health and wellness company, community and platform that has been changing people's lives with great nutrition products and a business opportunity for its independent distributors since 1980. The Company offers science-backed products to consumers in more than 90 markets through entrepreneurial distributors who provide one-on-one coaching and a supportive community that inspires their customers to embrace a healthier, more active lifestyle to live their best life. For more information, visit View source version on CONTACT: Media Contact: [email protected] KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: HEALTH FITNESS & NUTRITION RESEARCH SCIENCE PHARMACEUTICAL VITAMINS/SUPPLEMENTS BIOTECHNOLOGY SOURCE: Herbalife Ltd. Copyright Business Wire 2025. PUB: 06/11/2025 07:14 AM/DISC: 06/11/2025 07:12 AM